Sign in
CompletedPhase 3

Efficacy and Safety of Nifuroxazide in the Treatment of Hepatic Encephalopathy in Egyptian Patients With Liver Cirrhosis

Key facts

Who runs it
Cairo University
Where
Egypt1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 3
People taking part
80 people enrolled
Started
12 Mar 2023
Ended
29 Jul 2025
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Nifuroxazide
  • Lactulose
  • Rifaximin 550Mg Tab
Record updated
2 September 2025

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (9)Hide the full registry criteria

Who can take part

  • Patients suffering from liver cirrhosis aging above 18 years who will be admitted to hospital with neuropsychiatric condition suggestive of hepatic encephalopathy (grade II or III) confirmed by their known previous hepatic disease by history, clinical examination and laboratory investigations in the form of hyperammonemia with Model for End-Stage Liver Disease (MELD) score ≤ 25 and patients are able to swallow

Who cannot take part

  • Patients with previous intake of nifuroxazide and rifaximin within the last month
  • Alcohol consumption within prior 4 weeks
  • Degenerative central nervous system (CNS) disease
  • Any significant psychiatric illness
  • Presence of underlying renal impairment (serum creatinine ≥ 2 mg/dL)
  • Anemia with hemoglobin level < 7 g/dL
  • Patients with neurological or communication problems
  • Non-hepatic metabolic encephalopathy

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This is a pilot study designed to evaluate the efficacy and safety of nifuroxazide in the treatment of hepatic encephalopathy in patients with grade II-III hepatic encephalopathy

The 2 groups in the trial

  • lactulose plus Rifaximin plus nifuroxazideTreatment being tested

    Nifuroxazide dosing : 800 mg daily in 4 divided doses for 7 days Lactulose dosing : 30 to 60 mL PO TID to produce 2 to 3 semisoft stools per day. Rifaximin: 550 mg twice daily

    Treatment: Nifuroxazide, Lactulose, and Rifaximin 550Mg Tab

  • Lactulose plus RifaximinExisting treatment, for comparison

    Lactulose dosing : 30 to 60 mL PO TID to produce 2 to 3 semisoft stools per day. Rifaximin: 550 mg twice daily

    Treatment: Lactulose and Rifaximin 550Mg Tab

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
2 September 2025